Wainua (eplontersen subcutaneous injection) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has a transthyretin (TTR) pathogenic variant as confirmed by genetic testing
• Patient has symptomatic polyneuropathy
• Patient does not have a history of liver transplantation
• Medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis
• Medication is not used in combination with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Amvuttra [vutrisiran subcutaneous injection], Attruby [acoramidis tablets], Onpattro [patisiran intravenous infusion], Tegsedi [inotersen subcutaneous injection], or a tafamidis product)

Approval duration

1 year